Omni Health Inc (OMHE)

[mattsinvestmentclub]

This new distribution agreement represents the latest step towards Omni Health multi-year plan of making its next-generation anti-aging CBD products available for global distribution.
https://www.otcmarkets.com/stock/OMHE/news/Omni-Health-Inc-Announces-37-Million-Euro-Distribution-Agreement-Across-Europe?id=177968

RELIVATROL
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
INTRODUCTION:
Although rates of episiotomy are declining, post-episiotomy pain remains a complication in obstetric care. Current management includes NSAIDs and Benzocaine, but the use of Benzocaine has been linked to iatrogenic methemoglobinemia, with greatest risk in newborns. We hypothesized that a novel drug formulation, currently being investigated in diabetic neuropathy, can be used to attenuate post-episiotomy pain.
METHODS:
This pilot study was conducted in an outpatient obstetrics clinic on postpartum women aged between 18 and 39, who underwent vaginal delivery with episiotomy. Spray bottles with the investigational product were distributed to the patients to use without regulation. A survey to assess post-episiotomy pain using the Visual Analog Scale (VAS) was administered to the patients. Pain attenuation, time to pain attenuation, and quality of pain were measured.
RESULTS:
The cohort consisted of 25 women (including 5 non-responders). In responders, pain was attenuated by 4.0 scale units. Average time to analgesia was 9.25. Average pain ratings after treatment were compared to average pain ratings before treatment using a unidirectional paired sample t test (df=24). The average pain ratings for the entire cohort after administration of Relivatrol© were significantly lower than average pain rating prior to administration t (24)=7.41, P<.0001.
CONCLUSION:
We concluded that Relivatrol© significantly decreases post-episiotomy pain. Being a pilot study had multiple limitations; we developed a protocol for a larger investigation and are currently collecting data involving a greater number of subjects, a control arm, pharmacokinetic parameters, and an analysis of quality of life impact.